Roche’s (SIX:ROG) Phase II tiragolumab/Tecentriq (atezolizumab) combination as a first-line (1L) treatment in non-small cell lung cancer (NSCLC) needs longer-term efficacy data to solidify its potential, experts said. Still, the tolerability profile bodes well in comparison to other 1L therapies, they added.
The Phase II CITYSCAPE study (NCT03563716) results with tiragolumab, an anti-TIGIT antibody, with the anti-PDL1 checkpoint inhibitor Tecentriq were presented at the recently concluded American Society of Clinical Oncology (ASCO) Virtual Meeting. The presentation received positive analyst attention with one considering tiragolumab to be the “new darling of immunotherapy.” While experts found the combination’s efficacy encouraging, the relatively low Phase II patient numbers elicited some caution in efficacy in the context of longer-term survival data from several other large Phase III checkpoint inhibitor monotherapy and chemotherapy combination studies. The tiragolumab/Tecentriq combination is also in an ongoing Phase III SKYSCRAPER-01 study (NCT04294810) with a primary completion date in August 2022.
Nonetheless, experts found the Phase II dual immunotherapy strategy significant in light of its tolerability profile, especially in comparison to the anti-PD-1/anti-CTLA-4 combination of Bristol-Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab)/Yervoy (ipilimumab). Opdivo/Yervoy is the only dual immunotherapy combination sans chemotherapy approved in 1L NSCLC for metastatic patients with tumors expressing PD-L1 (≥1%).